GLP-1RA相关糖尿病性腰骶神经根丛神经病与腓总神经病的病例对照评估
回顾性病例对照研究(2005-2024)发现,GLP-1RA使用与糖尿病性腰骶神经根丛神经病(DLRPN)和腓总神经病(CFN)风险升高相关,DLRPN风险增加51%(OR 1.5),CFN风险增加30%(OR 1.3)。DLRPN更与HbA1c显著下降相关,CFN更与体重下降相关。
要点
- GLP-1RA使用与DLRPN风险增加51%相关(OR 1.5,95%CI 1.2-1.9)
- GLP-1RA使用与CFN风险增加30%相关(OR 1.3,95%CI 1.0-1.5)
- DLRPN患者HbA1c降幅大于CFN患者(2.4% vs 1.2%,p<0.001)
核心结论
- GLP-1RA使用与DLRPN和CFN发生风险升高相关。
- DLRPN及其相关神经微血管炎更与代谢变化(尤其HbA1c显著下降)相关,CFN具压迫性神经病特征且更受体重下降影响。
研究设计与样本
- 回顾性病例对照研究,纳入2005年4月28日至2024年12月25日诊断为DLRPN或CFN的患者,分析GLP-1RA暴露与临床特征。
- 对照组按年龄、性别、BMI和糖尿病状态匹配,评估GLP-1RA使用与神经病的关联。
主要发现
- 26例DLRPN患者共27次发作,症状中位起病时间为GLP-1RA启动后6个月(范围3-35个月)。
- DLRPN起病时HbA1c中位下降2.4%(范围1%-8.5%),BMI下降4单位(范围1-15),体重下降13.9%(范围3.6%-28.5%)。
- 5例神经活检中4例存在微血管炎。
- 77例CFN患者共82次发作,GLP-1RA平均使用时长15个月(范围1-112个月)。
- CFN患者HbA1c中位下降1.2%(范围-0.4%至5%),BMI下降4单位(范围0-15),体重下降15.7%(范围3.0%-37.0%)。
关键数值与推荐
- DLRPN患者HbA1c降幅大于CFN患者(2.4% vs 1.2%,p<0.001)。
- 所有发作均发生于2015年后,2015-2019年DLRPN 3例、CFN 7例,2020-2024年增至24例和70例,增幅分别为700%和900%。
- 发作期间未见新发NAION、黄斑水肿或视网膜病变。
临床怎么用
- 对使用GLP-1RA且出现腰骶神经根丛或腓总神经病症状的患者,应考虑药物相关神经病的可能性。
- DLRPN患者需关注HbA1c显著下降等代谢变化,CFN患者需关注体重下降因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used to treat obesity and diabetes. Semaglutide, a GLP-1RA, is linked to nonarteritic ischemic optic neuropathy (NAION), macular edema, and retinopathy. Because diabetic lumbosacral radiculoplexus neuropathy (DLRPN) and common fibular neuropathy (CFN) are associated with weight loss, we examined whether GLP-1RA usage is linked to these neuropathies. METHODS: We conducted a retrospective case-controlled study from April 28, 2005 (the first GLP-1RA Food and Drug Administration approval), to December 25, 2024. Patients diagnosed with DLRPN or CFN were analyzed for GLP-1RA exposure and clinical characteristics. A control group, matched for age, sex, body mass index (BMI), and diabetes status, was used to assess for an association with GLP-1RA use. RESULTS: We identified 26 individuals who developed 27 DLRPN episodes, with median symptom onset 6 months (range 3-35 months) after GLP-1RA initiation. At onset, they had a median glycated hemoglobin A1c (HbA1c) reduction of 2.4% (range 1%-8.5%) and a BMI decrease of 4 units (range 1-15), reflecting a 13.9% (range 3.6%-28.5%) weight loss. Microvasculitis was present in 4 of 5 nerve biopsies. Among 77 individuals with CFN, 82 episodes developed, with a mean GLP-1RA duration of 15 months (range 1-112 months). In individuals with CFN, the median HbA1c reduction was 1.2% (range -0.4% to 5%) and the BMI decrease was 4 units (range 0-15), corresponding to a 15.7% (range 3.0%-37.0%) weight loss. Patients with DLRPN experienced greater HbA1c reductions than patients with CFN (2.4% vs 1.2%, p < 0.001). New NAION, macular edema, or retinopathy were not seen with episodes. Compared with controls, GLP-1RA users were 51% more likely to develop DLRPN (odds ratio [OR] 1.5, 95% CI 1.2-1.9, p = 0.0008) and 30% more likely to develop CFN (OR 1.3, 95% CI 1.0-1.5, p = 0.018). All episodes occurred after 2015, with 3 DLRPN events and 7 CFN events occurring between 2015 and 2019, rising to 24 and 70 cases in 2020-2024, reflecting increases of 700% and 900%. DISCUSSION: GLP-1RA use is associated with an increased likelihood of DLRPN and CFN. DLRPN and its associated nerve microvasculitis seem more strongly linked to metabolic changes, particularly significant HbA1c reductions, while CFN has compressive neuropathy characteristics and is more influenced by weight loss.
引用
- Triplett JD, Pinto MV, Young NP, et al. GLP-1RA-Associated Diabetic Lumbosacral Radiculoplexus and Common Fibular Neuropathies: A Case-Control Evaluation. Neurology. 2025. PMID: 40694751. doi:10.1212/WNL.0000000000213916
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。